Publication | Closed Access

Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT

Health SciencesMedicineReceptor Tyrosine KinasePharmacologyAnti-cancer AgentTumor SuppressorStem CellsCell BiologyHcc CellsCancer Stem CellsEnhanced Inhibition